TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02078687

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enfamil HM fortifier, Mead Johnson
Description: Enfamil was added to a small amount of mothers expressed milk and given in a bottle or with a small cup every day. Group 2 (HMF) received 5 packets each day for 4 month containing; 17.5 kcal, 1.375 g protein/ 5 packets

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enfalac Premature Formula, Mead Johnson Nutritionals
Description: Group 3 received Enfalac containing:~68 kcal, 2 g protein, 7.4 g carbohydrate, 3.5 g fat/ 100 ml

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mothers own milk
Description: Group 1 received mothers own milk without fortification

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mothers own milk
Description: Group 1 received mothers own milk without fortification
Study: NCT02438709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COX-2 inhibitor
Description: oral COX-2 inhibitor intake 60mg qd
Study: NCT03477864

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given via intraprostatic injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given via intraprostatic injection
Study: NCT01963611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copaxone 20 mg
Description: Plovamer acetate was administered at a dose of 3 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plovamer acetate 3 mg
Description: Plovamer acetate was administered at a dose of 10 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plovamer acetate 10 mg
Description: Plovamer acetate was administered as two subcutaneous injection of 10 mg weekly for 40 weeks up to a maximum of 14 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plovamer acetate 20 mg
Description: Copaxone was administered at a dose of 20 mg as subcutaneous injection once daily for 40 weeks up to a maximum of 14 months.
Study: NCT06006455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia LunulaLaser
Description: 405nm violet and 635nm red laser light therapy.
Study: NCT04736875

Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler ultrasound study
Description: Transcutaneous Doppler ultrasound (DUS) study was performed at the mid brachial artery to assess diameter, VF and RI, and at the mid segment of the efferent vein to assess the diameter and wall thickness.
Study: NCT02058095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is \>95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil.~At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil.~At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is \>95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo.~At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo.~At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.
Study: NCT02429466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine (SGI-110)
Description: SGI-110 will be given subcutaneously, daily, 30 mg/m2 on days (1-5) followed by cisplatin 100mg/m2 on day 8 every 4 weeks.
Study: NCT02479490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone + Everolimus
Description: Prednisone + Everolimus: Everolimus is formulated as tablets of 5-10 mg strength, blister-packed under aluminium foil in units of 10 tablets. Prednisone will be dispensed to patients at the dose of 5 mg twice daily (BID). Everolimus at dose of 10 mg (one 10 mg tablet or two 5 mg tablets). Both drugs will be self-administered orally, continuously from Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death or discontinuation for any other reason.~A treatment cycle consists of 28 days.
Study: NCT03477864

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Undergo SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Undergo SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Undergo SBRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 Monoclonal Antibody REGN2810
Description: Given IV
Study: NCT01390493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neurofeedback training
Description: training of individual alpha frequency, 10 sessions, each 15 min
Study: NCT03477864

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 Monoclonal Antibody REGN2810
Description: Given IV
Study: NCT03340610

Intervention type: DRUG
Group type: OTHER
Intervention: Alflibercept
Description: Intravitreal Injection
Study: NCT03109171

Intervention type: OTHER
Group type: OTHER
Intervention: Laryngopharyngeal sensory test
Description: The sensory measurements will include thresholds for psychophysical sensory thresholds at the velopharynx, hypopharynx and aryepiglottic folds

Intervention type: OTHER
Group type: OTHER
Intervention: Laryngopharyngeal sensory test
Description: The sensory measurements will include thresholds for psychophysical sensory thresholds at the velopharynx, hypopharynx and aryepiglottic folds
Study: NCT03584867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: refresher training at six months
Description: a 5 cycles of 30:2 compression to ventilation ratio will be offered to experimental group at six months from BLS certification.
Study: NCT04003233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDS
Description: The SDS will be added to a traditional growing rod (TGR) of 4.5 or 5.5mm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MID-C
Description: The MID-C system consists of a unilateral one-way ratchet rod that is connected to the spine with polyaxial connectors
Study: NCT00963274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Starting dose: 1.3 mg/sq m

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Starting dose: 8 mg/sq m
Study: NCT05779982

Intervention type: PROCEDURE
Intervention: Sentinel lymph node biopsy followed by axillary lymph node dissection
Description: This is a retrospective study to determine the feasibility of sentinel lymph node biopsy (SLNB) after neoadjuvant systemic therapy (NAST) according to response to NAST and breast cancer subtypes. All patients received SLNB followed by axillary lymph node dissection after NAST.
Study: NCT00777010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: carbohydrate restricted diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy high carbohydrate diet
Description: higher carbohydrate diet
Study: NCT01324232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-923-45
Description: AVP-923-45 (dextromethorphan 45 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-923-30
Description: AVP-923-30 (dextromethorphan 30 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-923-20
Description: AVP-923-20 (dextromethorphan 20 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
Study: NCT01168661

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Participants in this intervention arm will practice yoga (physical postures, breathing exercises, and meditation) \>= 5 times a week (twice in a supervised group and the rest on their own). Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. They will follow this schedule for 20 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness based cog psychotherapy
Description: Participants in this arm will attend a weekly group meeting to practice mindfulness based cognitive psychotherapy. They will also practice \>= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive psychotherapy
Description: Participants in this arm will attend a weekly group meeting to practice cognitive psychotherapy. They will also practice \>= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
Study: NCT01789814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Patients will be randomized to prasugrel or clopidogrel to assess the effect of these drugs on inhibition of platelet aggregation following the cessation of bivalirudin therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 600 mg as a loading dose immediately prior to the start of procedure and 75 mg daily thereafter
Study: NCT03317756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Educational Intervention
Description: Patients will view 5-6 videos that will help them with pre-identified patient barriers to achieving RA low disease activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Control
Description: Patients will receive an attention control
Study: NCT05325905

Intervention type: DIAGNOSTIC_TEST
Intervention: Gingival crevicular fluid sampling
Description: GCF sampling and clinical periodontal measurements were performed

Intervention type: DIAGNOSTIC_TEST
Intervention: Gingival crevicular fluid sampling
Description: GCF sampling and clinical periodontal measurements were performed

Intervention type: DIAGNOSTIC_TEST
Intervention: Gingival crevicular fluid sampling
Description: GCF sampling and clinical periodontal measurements were performed
Study: NCT03714529

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1
Description: IO103 is a anti-cancer therapy consisting of a synthetic PD-L1-derived peptide.
Study: NCT01317589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: T = 0~* start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~* breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~* if necessary increase dose strong opioid with 50%~T=2 3 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T=3 5 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methadone
Description: T = 0~* start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~* breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~* if necessary increase dose strong opioid with 50%~T=2 3 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T=3 5 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%
Study: NCT00798226

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: n-3 fatty acid
Description: Oral intake of 4 capsules daily from week 24 of gestation to 1 week after delivery

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: olive oil
Description: Oral intake of 4 capsules (1 g) daily from 24 weeks of gestation to 1 week after delivery
Study: NCT02042937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise to improve gluteus maximus recruitment
Study: NCT00944203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipomea pes-caprae ointment
Description: Ipomea pes-caprae ointment will be applied twice a day as an add-on therapy.
Study: NCT02330848

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Walnut Ad libitum diet
Description: Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet. Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum
Study: NCT01019447

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl Plus
Description: Triclosan-coated polyglactin 910 antimicrobial sutures (Vicryl Plus)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl
Description: Polyglactin 910 antimicrobial sutures (Vicryl)
Study: NCT04277845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib, Lenalidomide, Dexamethasone
Description: Bortezomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib, Lenalidomide, Dexamethasone
Description: Bortezomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone
Study: NCT00060346

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Rituximab is given intravenously. The initial rate is 50 mg/hr for the 1st hour. If no toxicity, the rate may be escalated in 50 mg/hr increments at 30-minute intervals to a maximum of 400 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr. If the patient experiences fever and rigors, the antibody infusion is discontinued. The severity of the side effects should be evaluated. If the symptoms improve, the infusion is continued initially at half the previous rate. Following the antibody infusion, the intravenous line should be maintained for medications as needed. If there are no complications after one hour of observation, the intravenous line may be discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide will be given at a dosage of 750 mg/m² intravenously on day 1 of each cycle (1 cycle =21 days) for 6 cycles. Dose is based on surface area calculated based on actual body weight.~The drug should be administered as a rapid IV infusion over 5 to 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be given intravenously at a dosage of 50 mg/m² on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Doxorubicin should be administered as a continuous infusion into tubing of a freely flowing intravenous line for 5 -15 minutes. Avoid extravasation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered at 100 mg/m² orally, days 1-5 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine will be administered 1.4 mg/m² intravenously (Maximum dose = 2.0 mg) on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Given as IV push over 1 minute, using extravasation precautions.
Study: NCT00957008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group weight loss program
Description: Participants will be asked to attend 14 one-and-half-hour group sessions at the University of South Carolina's Public Health Research Center (PHRC) over a 16 week period. After the groups end, they will be asked to take part in 6 telephone calls during their remaining 2 months in the program. They will also receive a weight loss manual.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group weight loss program plus use of the Senseware Armband
Description: Participants will be asked to attend 15 one-and-half-hour group sessions at the University of South Carolina's Public Health Research Center (PHRC) over a 17 week period. After the groups end, they will be asked to take part in 6 telephone calls during their remaining 2 months in the program. They will also receive a SenseWear Armband to wear during their 6 months in the program. One of these group sessions will be devoted to learning how to use the SenseWear Armband. They will be asked to wear the Armband regularly, upload data from the Armband to a web-based application, and input nutritional and health information into a personalized web account. They will receive a weight loss manual in addition to the group sessions and Armband.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the senseware armband alone program
Description: Participants will be asked to attend a one-hour group session at the University of South Carolina's Public Health Research Center (PHRC) to learn how to use the SenseWear Armband. They will then be asked to take part in a follow-up telephone call one week after they start wearing the armband. For the 6 months they are in the program, they will be asked to wear the Armband regularly, upload data from the Armband to a web-based application, and input nutritional and health information into a personalized web account. They will also receive a weight loss manual in addition to the Armband.
Study: NCT03530371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: intranasal administration of 2.5µg/kg of dexmedetomidine to fall asleep the patients
Study: NCT04775329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin 1000mg OM
Study: NCT04672759

Intervention type: DRUG
Intervention: Durvalumab
Description: Patients receive durvalumab as an intravenous infusion over 60 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Intervention: Durvalumab
Description: Patients receive durvalumab as an intravenous infusion over 60 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Intervention: Durvalumab
Description: Durvalumab monotherapy or combined with chemotherapy and/or radiotherapy.

Intervention type: DRUG
Intervention: Durvalumab
Description: Durvalumab monotherapy or combined with chemotherapy and/or radiotherapy.
Study: NCT01423799

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplements containing arginine, n-3 and nucleotides
Description: Nutritional intervention with immuno-nutrients

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Isocaloric control
Description: Isocaloric and isonitrogenous control without immuno nutrients
Study: NCT00264875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: 75mg BID, titrated up to 300mg according to individual response and tolerability
Study: NCT02368054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Infiltration anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Infiltration anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline
Description: Infiltration anesthesia
Study: NCT04674592

Intervention type: OTHER
Intervention: Blood samples and biopsies
Description: Blood samples for analysis of biomarkers of muscle damage. Muscle biopsies for histological analysis of muscle damage.

Intervention type: OTHER
Intervention: Blood samples and biopsies
Description: Blood samples for analysis of biomarkers of muscle damage. Muscle biopsies for histological analysis of muscle damage.

Intervention type: OTHER
Intervention: Blood samples and biopsies
Description: Blood samples for analysis of biomarkers of muscle damage. Muscle biopsies for histological analysis of muscle damage.
Study: NCT05373147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: αPD1-MSLN-CAR T cells
Description: The safety and efficacy of αPD1-MSLN-CAR T cells will be assessed in a standard 3+3 dose escalation approach. Four doses of CAR T cells will be evaluated in this study: 1×10\^5 CAR+ T cells/kg, 3×10\^5 CAR+ T cells/kg, 1×10\^6 CAR+ T cells/kg, and 3×10\^6 CAR+ T cells/kg.